header logo image


Page 49«..1020..48495051..60..»

Archive for the ‘Regenerative Medicine’ Category

Six steps to fighting non-compliant cell therapy treatments. — The stuff of grey shades, spades, ivory towers and (ahem) balls.

Sunday, December 2nd, 2012
Tweet 


Today an article entitled "Professors Critique Stem Cell Medical Tourism" appeared in the online version of The Harvard Crimson summarizing a recent panel discussion hosted in least in part by Harvard Law School assistant professor I. Glenn Cohen and University of Alberta law professor Timothy Caulfield.  The article concludes thusly:

The panelists emphasized that more accurate information should be provided to the public regarding stem cell treatments.

Certainly what Cohen and Caulfield concluded is true.  It has now been true for several years.  We keep saying it.  But are we listening to ourselves?  Are we doing anything meaningful to address this?  If so, is it enough?

Sadly (in my opinion, of course) the answer is 'not nearly enough'.*

For several years now, experts and organizations in the cell therapy sector have been saying that more must be done to educate and assist patients who are seeking stem cell or other cell-based treatments which do not comply with existing regulation and/or widely accepted medical or clinical research practices (hereafter called "non-compliant cell therapies").  
In my opinion, attempts to address this need by the sector's professional organizations, while important, have been unnecessarily feeble, not gone nearly far enough, and legitimately appear by many to be high-minded and pedantic. 



Almost all efforts to-date to address this issue by ISSCR, CIRM, ISCT and others including authors such as Caufield - as laudable and needed as they are - have been focused on helping distinguish between compliant and non-compliant treatments (and providers).  This is certainly much needed.  But what is left, I submit, is an even greater unmet need.


What almost all efforts to-date have failed to recognize or address is that where real help is needed is in helping patients distinguish between the many shades of grey among non-compliant treatments (and providers).

Emerging organizations like ICMS (now in partnership with AABB) have recognized and attempted to address this unmet need through a commitment to create some level of certification, accreditation or standardization of clinics participating in this business of selling non-compliant cell therapies.

While their intentions appear on-target as one meaningful way to address this unmet need and certainly their willingness to tackle this issue in a bold way is to be lauded, the ICMS is inexperienced and underfunded.  I remain hopeful that now through their new partnership with AABB they will be able to provide something that really addresses this unmet need but the jury remains out on whether they will succeed.
Anyone who has followed this blog and/or my threads on LinkedIn know I have been thinking about and discussing this issue for some time. In a desire to move to very concrete suggestions, I want to recommend the following 6 steps to my industry colleagues and professional organizations:

1.  50 shades of grey. Let's admit that this issue is not black-and-white but, as is almost always, involves a broad spectrum of grey in the middle.  


In addition to helping patients distinguish between compliant and non-compliant treatments (and providers) there are a lot of ways to help patients distinguish between non-compliant cell therapy  treatments (and providers) which are more or less risky.  


Let me use examples.  

On the one end of the non-compliant spectrum I would put forward a clinical like Okyanos Heart Institute which (as I understand it) intends to provide cell therapy treatments in the Bahamas to US patients using the Cytori system for cardiac conditions as soon as such treatments are perfectly legal and available to European patients but years before such treatments will be available in the US.  
Non-compliant?  Yes.  But certainly no evidence I'm aware of to support a belief that seeking treatment from them would be any more risky than travelling to Europe to receive the same treatment in a manner perfectly compliant with European regulations.
On the other end of the spectrum are the kinds of clinics highlighted recently by 60 minutes or which are the subject of ongoing lawsuits.

In between - in my opinion - are clinics like Stem Cell Institute and StemCellMD.

2.  Step out of the ivory tower.  Let's recognize that in certain circumstances patients are going to go pay for non-compliant cell therapies and we must do more to help these patients than simply shake our finger and tell them they mustn't.
For some, helping patients distinguish between the better and worst non-compliant clinics might involve a fair amount of nose-pinching but this is the equivalent of the methadone clinic for heroine addicts.  By supporting the better of two evils we are not endorsing it as 'good', we are simply recognizing it is better.

This is a recognition that we cannot just abandon people because they made (or are going to make) decisions with which we ultimately disapprove.   It is a recognition that sometimes the most righteous thing to do is not only to help people do what we would ideally want them to do but to help them do the best they can in their circumstances and on their terms - even terms with which we may ultimately disagree.


3.  A risk-based strategy.  Let's recognize that even the FDA triages their response to non-compliance and we would do well to do the same.  As a regulated industry we are perfectly comfortable with risk-based assessments and it should be applied here.  
Rather than treating all non-compliance as equally evil, let's apply some risk-based analysis to the situation and develop a strategy to root out the worst (highest-risk) offenders.  
4.  This is not just about tourism anymore - the problem has come home to roost. Let's recognize that this is no longer just a problem of patients leaving a regulated jurisdiction seeking a non-compliant treatment in a jurisdiction with no or more permissive regulation.  
Non-compliant treatments are growing rapidly even in the most highly regulated jurisdictions.  No where is this more true than in the United States.
5. Take responsibility.  Let's recognize that we cannot expect our regulatory enforcement agencies to do it all.  They are under-staffed and under-funded.  They - and the people we all serve - need our active participation in dealing with offenders and those risking patient safety.  
From a self-interested perspective, we owe it to our industry to help crack down on those who put the credibility and legitimacy of cell therapies at highest risk.
6.  Let's grow a pair and call a spade a spade.  If a non-compliant clinic is providing treatments that we believe represent a high-risk to patient safety and the industry's credibility, let's have the b*lls to call them on it.  They can't sue everyone.  
ISSCR backed down on their stem cell tourism initiative after being threatened by lawsuits. Who has stepped up in their absence?  Individual bloggers and authors like Paul Knoeplfer, Alexey Bresenev, Leigh Turner, and myself all who have been threatened with litigation several times for having the audacity to call certain non-compliant clinics out for what we deem - in our own risk-based analysis - to be the worst offenders.  

By way of example, several of my colleagues have recently committed to doing all they can do to call out David Steenblock and his non-compliant cell therapy treatments, many of which are provided at his clinic in California for a plethora of conditions.  In their opinion, many of his treatments represent some of worst examples of non-compliance in the United States right now.  There are many faces or fronts to his practice including http://www.davidsteenblock.comhttp://www.stemcellmd.org, http://www.strokedoctor.com, http://www.davidsteenblock.net, etc.

If, as an industry, we act with more cohesion (collaboratively applying a risk-based assessment of non-compliant clinics) and speak with a more cohesive voice in terms of calling out those clinics and treatments which we conclude pose the greatest risk based on an objective set of criterion, this will present a multi-pronged, formidable and existential threat to clinics that they can't ignore or threaten away.
___

I will be taking these 6 recommendations to any organization who will listen.  I hope you will consider doing the same.



In the meantime - as always - I welcome your comments.


___

* This is my opinion not necessarily the opinion of any clients I represent or organizations I serve. Judge me - not them - accordingly.


http://www.celltherapyblog.com hosted by http://www.celltherapygroup.com

Source:
http://feedproxy.google.com/~r/CellTherapyBlog/~3/2b8Ffw4b1pU/six-steps-to-fighting-non-compliant.html

Read More...

Six steps to fighting non-compliant cell therapy treatments. — The stuff of grey shades, spades, ivory towers and (ahem) balls.

Sunday, December 2nd, 2012
Tweet 


Today an article entitled "Professors Critique Stem Cell Medical Tourism" appeared in the online version of The Harvard Crimson summarizing a recent panel discussion hosted in least in part by Harvard Law School assistant professor I. Glenn Cohen and University of Alberta law professor Timothy Caulfield.  The article concludes thusly:

The panelists emphasized that more accurate information should be provided to the public regarding stem cell treatments.

Certainly what Cohen and Caulfield concluded is true.  It has now been true for several years.  We keep saying it.  But are we listening to ourselves?  Are we doing anything meaningful to address this?  If so, is it enough?

Sadly (in my opinion, of course) the answer is 'not nearly enough'.*

For several years now, experts and organizations in the cell therapy sector have been saying that more must be done to educate and assist patients who are seeking stem cell or other cell-based treatments which do not comply with existing regulation and/or widely accepted medical or clinical research practices (hereafter called "non-compliant cell therapies").  
In my opinion, attempts to address this need by the sector's professional organizations, while important, have been unnecessarily feeble, not gone nearly far enough, and legitimately appear by many to be high-minded and pedantic. 



Almost all efforts to-date to address this issue by ISSCR, CIRM, ISCT and others including authors such as Caufield - as laudable and needed as they are - have been focused on helping distinguish between compliant and non-compliant treatments (and providers).  This is certainly much needed.  But what is left, I submit, is an even greater unmet need.


What almost all efforts to-date have failed to recognize or address is that where real help is needed is in helping patients distinguish between the many shades of grey among non-compliant treatments (and providers).

Emerging organizations like ICMS (now in partnership with AABB) have recognized and attempted to address this unmet need through a commitment to create some level of certification, accreditation or standardization of clinics participating in this business of selling non-compliant cell therapies.

While their intentions appear on-target as one meaningful way to address this unmet need and certainly their willingness to tackle this issue in a bold way is to be lauded, the ICMS is inexperienced and underfunded.  I remain hopeful that now through their new partnership with AABB they will be able to provide something that really addresses this unmet need but the jury remains out on whether they will succeed.
Anyone who has followed this blog and/or my threads on LinkedIn know I have been thinking about and discussing this issue for some time. In a desire to move to very concrete suggestions, I want to recommend the following 6 steps to my industry colleagues and professional organizations:

1.  50 shades of grey. Let's admit that this issue is not black-and-white but, as is almost always, involves a broad spectrum of grey in the middle.  


In addition to helping patients distinguish between compliant and non-compliant treatments (and providers) there are a lot of ways to help patients distinguish between non-compliant cell therapy  treatments (and providers) which are more or less risky.  


Let me use examples.  

On the one end of the non-compliant spectrum I would put forward a clinical like Okyanos Heart Institute which (as I understand it) intends to provide cell therapy treatments in the Bahamas to US patients using the Cytori system for cardiac conditions as soon as such treatments are perfectly legal and available to European patients but years before such treatments will be available in the US.  
Non-compliant?  Yes.  But certainly no evidence I'm aware of to support a belief that seeking treatment from them would be any more risky than travelling to Europe to receive the same treatment in a manner perfectly compliant with European regulations.
On the other end of the spectrum are the kinds of clinics highlighted recently by 60 minutes or which are the subject of ongoing lawsuits.

In between - in my opinion - are clinics like Stem Cell Institute and StemCellMD.

2.  Step out of the ivory tower.  Let's recognize that in certain circumstances patients are going to go pay for non-compliant cell therapies and we must do more to help these patients than simply shake our finger and tell them they mustn't.
For some, helping patients distinguish between the better and worst non-compliant clinics might involve a fair amount of nose-pinching but this is the equivalent of the methadone clinic for heroine addicts.  By supporting the better of two evils we are not endorsing it as 'good', we are simply recognizing it is better.

This is a recognition that we cannot just abandon people because they made (or are going to make) decisions with which we ultimately disapprove.   It is a recognition that sometimes the most righteous thing to do is not only to help people do what we would ideally want them to do but to help them do the best they can in their circumstances and on their terms - even terms with which we may ultimately disagree.


3.  A risk-based strategy.  Let's recognize that even the FDA triages their response to non-compliance and we would do well to do the same.  As a regulated industry we are perfectly comfortable with risk-based assessments and it should be applied here.  
Rather than treating all non-compliance as equally evil, let's apply some risk-based analysis to the situation and develop a strategy to root out the worst (highest-risk) offenders.  
4.  This is not just about tourism anymore - the problem has come home to roost. Let's recognize that this is no longer just a problem of patients leaving a regulated jurisdiction seeking a non-compliant treatment in a jurisdiction with no or more permissive regulation.  
Non-compliant treatments are growing rapidly even in the most highly regulated jurisdictions.  No where is this more true than in the United States.
5. Take responsibility.  Let's recognize that we cannot expect our regulatory enforcement agencies to do it all.  They are under-staffed and under-funded.  They - and the people we all serve - need our active participation in dealing with offenders and those risking patient safety.  
From a self-interested perspective, we owe it to our industry to help crack down on those who put the credibility and legitimacy of cell therapies at highest risk.
6.  Let's grow a pair and call a spade a spade.  If a non-compliant clinic is providing treatments that we believe represent a high-risk to patient safety and the industry's credibility, let's have the b*lls to call them on it.  They can't sue everyone.  
ISSCR backed down on their stem cell tourism initiative after being threatened by lawsuits. Who has stepped up in their absence?  Individual bloggers and authors like Paul Knoeplfer, Alexey Bresenev, Leigh Turner, and myself all who have been threatened with litigation several times for having the audacity to call certain non-compliant clinics out for what we deem - in our own risk-based analysis - to be the worst offenders.  

By way of example, several of my colleagues have recently committed to doing all they can do to call out David Steenblock and his non-compliant cell therapy treatments, many of which are provided at his clinic in California for a plethora of conditions.  In their opinion, many of his treatments represent some of worst examples of non-compliance in the United States right now.  There are many faces or fronts to his practice including http://www.davidsteenblock.comhttp://www.stemcellmd.org, http://www.strokedoctor.com, http://www.davidsteenblock.net, etc.

If, as an industry, we act with more cohesion (collaboratively applying a risk-based assessment of non-compliant clinics) and speak with a more cohesive voice in terms of calling out those clinics and treatments which we conclude pose the greatest risk based on an objective set of criterion, this will present a multi-pronged, formidable and existential threat to clinics that they can't ignore or threaten away.
___

I will be taking these 6 recommendations to any organization who will listen.  I hope you will consider doing the same.



In the meantime - as always - I welcome your comments.


___

* This is my opinion not necessarily the opinion of any clients I represent or organizations I serve. Judge me - not them - accordingly.


http://www.celltherapyblog.com hosted by http://www.celltherapygroup.com

Source:
http://feedproxy.google.com/~r/CellTherapyBlog/~3/2b8Ffw4b1pU/six-steps-to-fighting-non-compliant.html

Read More...

Stem Cells and Insurance – Video

Saturday, December 1st, 2012


Stem Cells and Insurance
The current state of the economy is uncertain and cause for concern for any business. Stem cell banks are no exception. When banks close down for any reason, its customers are immediately outraged about the money they have deposited. In the event of a stem cell bank failure, the investment is much more precious. These cells are of great interest in research because of their immense potential in regenerative medicine and other applications. A contingency plan needs to be implemented in order to protect these resources that are being used to find valuable treatments for otherwise incurable diseases.From:Alexandra KellyViews:2 0ratingsTime:02:53More inPeople Blogs

Go here to read the rest:
Stem Cells and Insurance - Video

Read More...

SCMOM 2012_UC Davis – Wheelock – Video

Thursday, November 29th, 2012


SCMOM 2012_UC Davis - Wheelock
UC Davis is playing a leading role in regenerative medicine, with nearly 150 scientists working on a variety of stem cell-related research projects at campus locations in both Davis and Sacramento. The UC Davis Institute for Regenerative Cures, a facility supported by the California Institute for Regenerative Medicine (CIRM), opened in 2010 on the Sacramento campus. This $62 million facility is the university #39;s hub for stem cell science. It includes Northern California #39;s largest academic Good Manufacturing Practice laboratory, with state-of-the-art equipment and manufacturing rooms for cellular and gene therapies. UC Davis also has a Translational Human Embryonic Stem Cell Shared Research Facility in Davis and a collaborative partnership with the Institute for Pediatric Regenerative Medicine at Shriners Hospital for Children Northern California. All of the programs and facilities complement the university #39;s Clinical and Translational Science Center, and focus on turning stem cells into cures. http://www.ucdmc.ucdavis.edu/stemcellresearch Presenter: Vicki L. Wheelock, MD, Clinical Professor, Neurology, Director, HDSA Center of Excellence, Principle Investigator, CIRM Grant DR2A-05415, UC Davis Health SystemFrom:AllianceRegenMedViews:1 0ratingsTime:12:18More inScience Technology

See more here:
SCMOM 2012_UC Davis - Wheelock - Video

Read More...

SCMOM 2012_Owl Biomedical – Video

Thursday, November 29th, 2012


SCMOM 2012_Owl Biomedical
Owl biomedical is an emerging company commercializing an innovative high-speed, disposable cartridge-based cell sorting platform called the Nanosorter®. The Nanosorter® enables rapid processing of large numbers of cells safely without aerosols and in a simple, readily deployable and easy to use system. The Nanosorter® platform uniquely combines the world #39;s fastest microvalve (fabricated within a microchip) and the well-proven principles of fluorescence-activated sorting of cells. Cells purified using the Nanosorter® can be employed for a wide variety of commercial applications, including: adoptive immunotherapy for treatment of cancer, stem cell therapies for regenerative medicine (eg stroke, limb ischemia, wound healing), cell-based cancer diagnostics, and a wide variety of cell-based applied research applications. Owl biomedical was founded in 2011 and is based in Santa Barbara, California. http://www.owlbiomedical.com Presenter: Jim Linton, Ph.D., MBA, President and Chief Business Officer, Owl BiomedicalFrom:AllianceRegenMedViews:7 1ratingsTime:15:31More inScience Technology

See the rest here:
SCMOM 2012_Owl Biomedical - Video

Read More...

SCMOM 2012_Cedars-Sinai Regenerative Medicine Institute – Video

Thursday, November 29th, 2012


SCMOM 2012_Cedars-Sinai Regenerative Medicine Institute
The Cedars-Sinai Regenerative Medicine Institute (RMI) brings together research faculty and clinicians to provide a true "bench to bedside" organization. We have five major programs of research: (i) Brain, (ii) Eye, (iii) Pancreas and Liver, (iv) Blood and (v) Skeletal. Working within each of these programs benefits from our core facilities with a focus on generating induced pluripotent stem cells from adult human skin samples and optimizing differentiation into various tissues of the human body of interest to the six programs. The pluripotent cells are used to both increase our understanding of human diseases through modeling, and provide a foundation for pre-clinical studies aimed at establishing and validating cellular therapeutic approaches to human illness. http://www.cedars-sinai.edu/Research-and-Education/Institutes/Regenerative-Medicine-Institute Presenter: Clive Svendsen, Ph.D., Director, Cedars-Sinai Regenerative Medicine InstituteFrom:AllianceRegenMedViews:1 0ratingsTime:13:27More inScience Technology

Read the original post:
SCMOM 2012_Cedars-Sinai Regenerative Medicine Institute - Video

Read More...

SCMOM 2012_NeoStem – Video

Thursday, November 29th, 2012


SCMOM 2012_NeoStem
NeoStem, Inc. is an emerging technology leader in the fast-developing cell therapy market. Its business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC, with a medically important cell therapy product development program. NeoStem #39;s most clinically advanced therapeutic, AMR-001, is being developed at its Amorcyte subsidiary, which is enrolling patients in a Phase 2 trial for preservation of heart function after a heart attack. Athelos Corporation, also a NeoStem subsidiary, is in early stage clinical exploration of a T-cell therapy for autoimmune conditions. Pre-clinical assets include our VSELTM Technology platform and our mesenchymal stem cell product candidate for regenerative medicine. http://www.neostem.com Presenter: Jonathan Sackner-Bernstein, NeoStem, Inc.From:AllianceRegenMedViews:4 1ratingsTime:14:54More inScience Technology

Originally posted here:
SCMOM 2012_NeoStem - Video

Read More...

SCMOM 2012_ViaCyte – Video

Thursday, November 29th, 2012


SCMOM 2012_ViaCyte
ViaCyte, Inc., a leader in the emerging field of regenerative medicine, is headquartered in San Diego, California. ViaCyte #39;s innovative product is based on the differentiation of stem cells into pancreatic beta cell precursors (PEC-01), with subcutaneous implantation in a retrievable and immune-isolating encapsulation medical device. Once implanted, the precursor cells mature into endocrine cells that secrete insulin in a regulated manner to control blood glucose levels. ViaCyte #39;s goal is a product that can free Type 1 and 2 diabetic patients from long-term insulin dependence. ViaCyte has received substantial financial support from both CIRM and JDRF. http://www.viacyte.com Presenter: Paul Laikind, President and CEO, ViaCyteFrom:AllianceRegenMedViews:3 1ratingsTime:16:42More inScience Technology

View original post here:
SCMOM 2012_ViaCyte - Video

Read More...

SCMOM 2012_Regenerative Patch Technologies – Video

Thursday, November 29th, 2012


SCMOM 2012_Regenerative Patch Technologies
Regenerative Patch Technologies was formed to advance development of a composite RPE cell-membrane technology currently supported by a disease team award to the University of Southern California, the University of California, Santa Barbara, and the California Institute of Technology from the California Institute of Regenerative Medicine. The technology utilizes polarized RPE cells derived from human embryonic stem cells together with an ultrathin biocompatible parylene membrane as a replacement for the defective Bruch #39;s membrane RPE cell complex often observed in patients with the atrophic form of age related macular degeneration. The project is progressing through preclinical studies to enable IND filing in 2014. http://www.regenerativepatch.com Presenter: Jane Lebkowski, President and CSO, Regenerative Patch TechnologiesFrom:AllianceRegenMedViews:11 1ratingsTime:15:22More inScience Technology

Link:
SCMOM 2012_Regenerative Patch Technologies - Video

Read More...

SCMOM 2012_Stanford Cardiovascular Institute – Video

Thursday, November 29th, 2012


SCMOM 2012_Stanford Cardiovascular Institute
Stanford Cardiovascular Institute (CVI) is the nucleus for cardiovascular research at Stanford University. Formed in 2004, the Cardiovascular Institute is home to Stanford #39;s myriad cardiovascular-related adult and pediatric research, clinical, and educational programs, centers and laboratories, as well as over 500 Stanford basic scientists, graduate students, clinician scientists, and other researchers in heart and vessel disease and prevention. Within the area of cardiac regenerative medicine, the Stanford CVI has significant research endeavors involving human pluripotent stem cells for (1) cardiovascular disease modeling, (2) drug screening and discovery, and (3) personalized cell therapy. Recently, Stanford CVI investigators received a $20 million CIRM Disease Team Therapy Award for performing pre-IND work that would enable the first-in-man clinical trial involving injection of human embryonic stem cell-derived cardiomyocytes for patients with heart failure. wulab.stanford.edu Presenter Joseph Wu, Associate Professor, Cardiovascular Medicine, Stanford University School of MedicineFrom:AllianceRegenMedViews:3 0ratingsTime:17:06More inScience Technology

Go here to read the rest:
SCMOM 2012_Stanford Cardiovascular Institute - Video

Read More...

SCMOM 2012_Regen BioPharma, Inc. – Video

Thursday, November 29th, 2012


SCMOM 2012_Regen BioPharma, Inc.
The Regen BioPharma business model is to take multiple stem cell therapeutics to and through the human "safety and signal of efficacy" stage (Phase I/II clinical trials). The approach is a highly focused analysis of issued patents in regenerative medicine, identification and acquisition of undervalued assets that have demonstrated proof of concept, and forming companies around these assets. Having assembled a core infrastructure specialized in obtaining regulatory approval and executing clinical trials in cell therapy, we aim to act as a "superincubator" that within 18 - 24 months grows technologies from laboratory to an asset ready for spin-off or sale to feed the pipeline of Big Pharma. http://www.regenbiopharma.com Presenter: J. Christopher Mizer, President, Regen BioPharma, Inc.From:AllianceRegenMedViews:4 1ratingsTime:09:13More inScience Technology

More here:
SCMOM 2012_Regen BioPharma, Inc. - Video

Read More...

Stem Cells for Regenerative Medicine – Video

Thursday, November 29th, 2012


Stem Cells for Regenerative Medicine
Stem cell banks might one day be used to meet the tissue-transplant needs of most of the population. Just as there are universal blood donors, cells from universal donors could be used to develop induced pluripotent stem cells (iPS cells) or adult stem cells for use in repairing the nervous system, the heart or other organs. Off-the-shelf cell lines could be made available for recipients in a timely way, with matching likely to lower risk of transplant rejection. UCSF stem cell scientist Bruce Conklin, MD, discusses.From:UCSFPublicAffairsViews:2 0ratingsTime:03:29More inEducation

Here is the original post:
Stem Cells for Regenerative Medicine - Video

Read More...

Stem Cells 101 – Mayo Clinic – Video

Thursday, November 29th, 2012


Stem Cells 101 - Mayo Clinic
Stem cells and their use in regenerative medicine have been in the media a lot lately. But, what exactly does it mean? Physicians and researchers in the Center for Regenerative Medicine at Mayo Clinic say it has to do with developing completely new ways to treat and manage chronic diseases such as diabetes, heart failure or even degenerative nerve, bone and joint conditions. Experts worldwide will meet this December for the World Stem Cell Summit, where they #39;ll explore and share ideas about regenerative medicine. Here are the basics of how this research benefits patients.From:mayoclinicViews:6 0ratingsTime:02:20More inScience Technology

Original post:
Stem Cells 101 - Mayo Clinic - Video

Read More...

The Cure: A Documentary on Regenerative Medicine (Part 1) – Video

Tuesday, November 27th, 2012


The Cure: A Documentary on Regenerative Medicine (Part 1)
Filmmaker David Alvarado tells the remarkable, behind-the-scenes story on the founding of the Silicon Valley Institute of Regenerative Medicine. Through a public/private partnership with Santa Clara Valley Medical Center, Stanford University, the County of Santa Clara, the Palo Alto VA and others, the Institute hopes to facilitate major breakthroughs in the treatment of spinal cord and other injuries using stem cells.From:VMCFoundationViews:2 0ratingsTime:07:07More inScience Technology

Link:
The Cure: A Documentary on Regenerative Medicine (Part 1) - Video

Read More...

Regenerative Therapy Using Blood-derived Stem Cells – Video

Friday, November 23rd, 2012


Regenerative Therapy Using Blood-derived Stem Cells
ll4.me Regenerative Therapy Using Blood-derived Stem Cells From the contents: Undertaking Regenerative Medicine Studies with Blood Stem Cells.- Defining Endothelial Progenitor Cells.- Blood-Derived ALDHhi Cells in Tissue Repair.- Blood-Derived Mesenchymal Stem Cells and Tissue Repair.- Animal Protein-Free Expansion of Human Mesenchymal Stem / Progenitor Cells.- Defining Hierarchies of Unrestricted Somatic Stem Cells and Mesenchymal Stem Cells in Cord Blood.- Induced Pluripotent Stem Cells from Blood.- Endothelial Progenitors and Repair of Cardiovascular Disease.- Bone Marrow-Derived Cells as Treatment Vehicles in the Central Nervous System.- Regenerative Potential of Blood Stem Cell Products Used in Hematopoietic Stem Cell Transplantation.- Concepts to Facilitate Umbilical Cord Blood Transplantation.- Cord Blood Banking for Regenerative Therapy.- Regulatory Questions in the Development of Blood Stem Cell Products for Regenerative Therapy.- Cell Therapy Regulations from a European Perspective.- EBMT Registry of Non-Hematopoietic Stem Cells and Regenerative Therapy (Cellular and Engineered Tissue Therapies in Europe). EAN/ISBN : 9781617794711 Publisher(s): Springer, Berlin, Springer, New York Discussed keywords: Stammzelle Format: ePub/PDF Author(s): Allan, David S. - Strunk, Dirk From the contents: Undertaking Regenerative Medicine Studies with Blood Stem Cells.- Defining Endothelial Progenitor Cells.- Blood-Derived ALDHhi Cells in Tissue Repair.- Blood-Derived Mesenchymal SteFrom:justinmclellan9865Views:0 0ratingsTime:00:08More inPeople Blogs

Read this article:
Regenerative Therapy Using Blood-derived Stem Cells - Video

Read More...

cord blood donation | How Cord Blood Stem Cell Can Bring Hope to People Suffering From Life – Video

Wednesday, November 21st, 2012


cord blood donation | How Cord Blood Stem Cell Can Bring Hope to People Suffering From Life
http://www.cordbloodrecommendation.com A large number of people die waiting for a transplant due to this reason. Well, there are still debates on this issue. Human umbilical cord blood cells are very rich in stem cells and progenitor cells which make them the perfect place to take cells from and then store them in a cord blood bank or a stem cells bank. There is also another option given by non-profit cord blood banks, of free programs through which one can store umbilical cord blood stem cell samples. Others choose to donate the blood to a public bank for the public good. Given the progress that stem cell research and regenerative medicine have attained at present, and the promise that they show for the future, stem cell transplants may one day provide a cure for type 1 diabetes, heart disease, and brain injury, among other potentially life threatening and debilitating illnesses and conditions with inadequate treatment options today. One study in particular by Wagner, et al. ""Settling on a name for your newborn is definitely something all parents spend time doing, but one decision that is rarely thought of or overlooked is saving your newborn #39;s cord blood. However, you can choose to make a once-in-a-lifetime decision to collect and store your baby #39;s cord blood stem cells after the birth of your newborn baby. It is able to kill either normal or cancer-producing blood cells of the bone marrow. Your child #39;s umbilical cord blood contains special cells known as stem cells. Thus, it ...From:Alexander santafeViews:0 0ratingsTime:01:31More inScience Technology

The rest is here:
cord blood donation | How Cord Blood Stem Cell Can Bring Hope to People Suffering From Life - Video

Read More...

stem cell | Advantages Of Cord Blood Banking – Video

Wednesday, November 21st, 2012


stem cell | Advantages Of Cord Blood Banking
http://www.cordbloodrecommendation.com Programs Available to Store the Blood There are a small number of programs in the US currently (December 2011) that save cord blood. Before you decide on a specific cord blood bank, contact the AABB to determine if the private blood bank is accredited or if it has any complaints lodged against the facility by other patrons. It really should be observed that the technique has a high risk of complication. Keep in mind that cord blood storage acts as an insurance policy for your family, so consider any other factors before immediately determining not to store your child #39;s cord blood simply because of price. One more cord blood donation might just be enough to save another life. Given the progress that stem cell research and regenerative medicine have attained at present, and the promise that they show for the future, stem cell transplants may one day provide a cure for type 1 diabetes, heart disease, and brain injury, among other potentially life threatening and debilitating illnesses and conditions with inadequate treatment options today. In addition, you have to decide well in advance of the due date because once you lose the precious blood, you cannot regain it. The patient no longer needs to wait for a donor; he can be his own donor if his cord blood had been preserved after his birth. The ultimate decision to bank cord stem cells or not is a personal decision as to what is deemed appropriate for that particular family, but in making that ...From:loshoteles enmedellinViews:0 0ratingsTime:01:31More inScience Technology

Continue reading here:
stem cell | Advantages Of Cord Blood Banking - Video

Read More...

Nose cell transplant enables paralysed dogs to walk – Video

Monday, November 19th, 2012


Nose cell transplant enables paralysed dogs to walk
cientists have reversed paralysis in dogs after injecting them with cells grown from the lining of their nose. The pets had all suffered spinal injuries which prevented them from using their back legs. The Cambridge University team is cautiously optimistic the technique could eventually have a role in the treatment of human patients. The study is the first to test the transplant in "real-life" injuries rather than laboratory animals. Treadmill Of 34 pet dogs on the proof of concept trial, 23 had the cells transplanted into the injury site - the rest were injected with a neutral fluid. Many of the dogs that received the transplant showed considerable improvement and were able to walk on a treadmill with the support of a harness. None of the control group regained use of its back legs. The research was a collaboration between the MRC #39;s Regenerative Medicine Centre and Cambridge University #39;s Veterinary School. Professor Robin Franklin, a regeneration biologist at the Wellcome Trust-MRC Stem Cell Institute and report co-author, said: #39;Our findings are extremely exciting because they show for the first time that transplanting these types of cell into a severely damaged spinal cord can bring about significant improvement. "We #39;re confident that the technique might be able to restore at least a small amount of movement in human patients with spinal cord injuries but that #39;s a long way from saying they might be able to regain all lost function. #39; Prof Franklin said the procedure ...From:NEWSHD2012Views:0 0ratingsTime:00:21More inPets Animals

Follow this link:
Nose cell transplant enables paralysed dogs to walk - Video

Read More...

Call for Nominations: "Stem Cell Person of the Year" – Video

Saturday, November 17th, 2012


Call for Nominations: "Stem Cell Person of the Year"
UC Davis stem cell scientist Paul Knoepfler is seeking nominees for the 2012 "Stem Cell Person of the Year." He created the new award to recognize an individual who has made an outstanding difference in the field of stem cell-based cellular and regenerative medicine. Nominees can be scientists, patient advocates, individuals from industry or just about anyone who has made the stem cell field better. The award includes a $1000 cash prize.From:UCDavisHealthViews:2 0ratingsTime:01:48More inScience Technology

Go here to see the original:
Call for Nominations: "Stem Cell Person of the Year" - Video

Read More...

Jill Helms, "Forever Young: The New Frontier of Stem Cell Medicine" – Video

Thursday, November 15th, 2012


Jill Helms, "Forever Young: The New Frontier of Stem Cell Medicine"
The good part about getting older is that we gain some wisdom and patience. The bad part is that our bodies start to wear out. But what if we could revitalize our damaged bits back to a healthy state? Come hear what the field of Regenerative Medicine is striving to achieve, and learn how it all begins with the stem cell. Jill Helms is a professor in Plastic and Reconstructive Surgery in the department of surgery at Stanford University #39;s School of Medicine. This Classes Without Quizzes lecture was filmed on location at Stanford Reunion Homecoming 2012 by the Stanford Alumni Association.From:StanfordAlumniViews:11 0ratingsTime:54:05More inEducation

Originally posted here:
Jill Helms, "Forever Young: The New Frontier of Stem Cell Medicine" - Video

Read More...

Page 49«..1020..48495051..60..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick